ALS drug edaravone shows promise in slowing disease progression
NCT ID NCT00424463
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tested the drug edaravone (MCI-186) in 181 people with ALS, a progressive nerve disease. Participants received either edaravone or a placebo through IV infusions over 24 weeks. The goal was to see if edaravone could slow the decline in physical function. Results suggested a modest benefit in some patients, but the effect was not large and the drug requires ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Hospital Organization Miyagi National Hospital
Watari-gun, Miyagi, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Edaravone (also known as MCI-186 or Radicut)
What this could lead to
If successful, this could confirm edaravone as a treatment that slows the progression of ALS, helping patients maintain function longer.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all ALS patients. The benefit was modest and only seen in a specific subgroup. Edaravone requires regular IV infusions and may cause side effects like bruising or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.